Gemtuzumab: all 73 studies that test it

Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingNCT06917911Phase 2
• A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaRecruitingNCT06448013Phase 1
• CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLRecruitingNCT05558124Phase 1
• Treatment Study for Children and Adolescents With Acute Promyelocytic LeukemiaRecruitingNCT04793919Phase 2
• Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)RecruitingNCT04385290Phase 1/2
• Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AMLRecruitingNCT04168502Phase 3
• CLAG-GO for Patients With Persistent, Relapsed or Refractory AMLRecruitingNCT04050280Phase 2
• Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid LeukemiaRecruitingNCT03737955Phase 2
• Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaRecruitingNCT01409161Phase 2
• Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT00801489Phase 2
• Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113CompletedNCT04070768Phase 1Results posted
• Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction TherapyCompletedNCT03839446Phase 2Results posted
• Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AMLCompletedNCT03727750Phase 4Results posted
• Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid NeoplasmCompletedNCT03531918Phase 1/2Results posted
• OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03390296Phase 1/2Results posted
• Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03374332Phase 1/2Results posted
• Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia TreatmentCompletedNCT01698879Phase 2Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00968071Phase 2Results posted
• Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AMLCompletedNCT00895934Phase 1/2Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)CompletedNCT00882102Phase 2Results posted
• Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)CompletedNCT00766116Phase 1/2Results posted
• Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaTerminatedNCT00673153Phase 2Results posted
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaActive, not recruitingNCT00658814Phase 2Results posted
• S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaCompletedNCT00551460Phase 2Results posted
• Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00372593Phase 3Results posted
• Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic SyndromesCompletedNCT00274781Phase 2Results posted
• Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or MyelodysplasiaCompletedNCT00136084Phase 3Results posted
• S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AMLCompletedNCT00085709Phase 3Results posted
• Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AMLTerminatedNCT05716009Phase 1
• Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid LeukemiaCompletedNCT04915612Phase 1
• Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSTerminatedNCT04849910Phase 1/2
• Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04207190Phase 1
• CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminatedNCT03904251Phase 1
• Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaCompletedNCT03900949Phase 1
• Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03848754Phase 1
• Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeCompletedNCT03672539Phase 2
• International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingNCT02724163Phase 3
• Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4CompletedNCT02473146Phase 2/3
• Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDSCompletedNCT02221310Phase 2
• DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AMLCompletedNCT02182596Phase 1/2
• SCT Plus Immune Therapy in Average Risk AML/MDSCompletedNCT02117297Phase 2
• Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid LeukemiaWithdrawnNCT01548911Phase 2
• LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)CompletedNCT01041040Phase 4
• Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
• Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionCompletedNCT00962767Phase 3
• Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene MutationCompletedNCT00893399Phase 3
• Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMMLTerminatedNCT00669890Phase 1
• Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid LeukemiaTerminatedNCT00660036Phase 1
• Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT00577694Phase 1
• NOPHO-AML 2004 Study for Children With Acute Myeloid LeukemiaCompletedNCT00476541Phase 3
• Gemtuzumab Ozogamicin Before Allogeneic Stem Cell TransplantationStatus unknownNCT00460447Phase 1/2
• Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00454480Phase 2/3
• Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With LeukemiaCompletedNCT00304447Phase 4
• A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid LeukemiaCompletedNCT00233909Phase 1/2
• Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSCompletedNCT00195000Phase 2
• Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)CompletedNCT00143975Phase 2
• Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00121303Phase 3
• Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaStatus unknownNCT00091234Phase 2/3
• Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00089050Phase 2
• Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic SyndromeCompletedNCT00077116Phase 2
• Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification TherapyCompletedNCT00070174Phase 2
• Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00052299Phase 3
• S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00049179Phase 2
• Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell TransplantCompletedNCT00044733Phase 2
• Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDSCompletedNCT00038831Phase 1/2
• Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)TerminatedNCT00038805Phase 2/3
• Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid LeukemiaCompletedNCT00037596Phase 2
• Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid LeukemiaCompletedNCT00037583Phase 2
• Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00028899Phase 1
• Gemtuzumab in Treating Patients With Myelodysplastic SyndromeStatus unknownNCT00022321Phase 2
• Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00017589Phase 2
• Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00008151Phase 2
• Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00006122Phase 2

← Gemtuzumab overview